Eliseo Salinas

The Group's principal activity is the researching, development and marketing of prescription medicines. The Group operations focuses on three therapeutic areas - central nervous system disorders, gastrointestinal and renal diseases. The Group's marketed products for such disorders include ADDERALL and ADDERALL XR, for attention deficit hyperactivity disorder, REMINYL for Alzheimer's, co-marketed with Johnson and Johnson and CARBATROL. for epilepsy. The Group is also developing a range of treatments for ADHD which may treat children, adolescents and adults extending the use of its current brand as well as researching non-scheduled compounds. The Group operates in the United Kingdom, the United States of America, France, Germany, Italy, Spain, Ireland, Canada, the Netherlands and the Cayman Islands.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Camp Nine, Inc. operates as a clinical stage biopharmaceutical company. The company through its subsidiary Relmada Therapeutics, Inc. focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. Camp Nine was founded on May 31, 2012 and is headquartered in New York, NY.

ViroChem Pharma, Inc. provides antiviral drug research and development services. The company provides R&D services on HIV/AIDS and hepatitis C. It was founded on April 8, 2004 and is headquartered in Laval, Canada.

Part of Pfizer Inc., Wyeth Research discovers and develops platforms encompassing pharmaceuticals. The private company is based in Cambridge, MA.

Relmada Therapeutics, Inc. is a holding company, which engages in the development of pharmaceutical drugs for the treatment of acute and chronic pains. It focuses in the developing of chronic pain due to cancer, musculoskeletal disorders, and peripheral neuropathy. The company was founded in 2000 and is headquartered in Blue Bell, PA.

Phoenixus AG operates as a research-based pharmaceutical company. It develops and commercializes treatments for diseases and conditions with limited or no treatment options. The firm's products include Daraprim and Vecamyl. The company was founded by Martin Shkreli on February 24, 2015 and is headquartered in Baar, Switzerland.

Vyera Pharmaceuticals LLC operates as a biopharmaceutical company that focuses on patients with unmet medical needs. Its products include Vecamyl and Daraprim. The firm engages in developing and commercializing treatments for serious diseases and conditions of therapeutic areas. The company was founded by Martin Shkreli in October 10, 2014 and is headquartered in New York, NY.

Fortuna Fix Ltd. engages in the regenerative medicine company with a patented direct cell reprogramming technology platform and a proprietary bio-scaffolding technology, for the treatment of neurodegenerative diseases and neurotrauma. Its programs include spinal cord injury and Parkinson's disease with on-going development efforts in stroke, traumatic brain injury, hearing loss and ALS. The company was founded on September 10, 2015 and is headquartered in London, the United Kingdom.